Newsmeme!
Discover News you didn't know existed
Byetta
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Amylin Pharmaceuticals Announces Positive Results From Dose-Ranging Clinical Study Of Pramlintide/Metreleptin ...
Published July 9, 2009, 6:09 am, PharmaceuticalOnline
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients.
US FDA accepts NDA for exenatide once weekly for review
Published July 9, 2009, 5:48 am, PharmaBiz
Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the US Food and Drug Administration (FDA).
Alkermes: NDA Not Enough
Published July 9, 2009, 5:37 am, Zacks.com via Yahoo! Finance
Our major concern about the program is the pancreatic inflammation reported for Byetta.
My Pharmiweb.com
Published July 9, 2009, 2:34 am, PharmiWeb
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).
Drug testing firm draws volunteers
Published July 9, 2009, 1:41 am, St. Louis Post-Dispatch
Ever wonder how pharmaceutical companies find volunteers to try out all those prescription drugs before they can pass Food and Drug Administration muster?
Health Buzz: Painkillers Get Warning and Other Health News
Published July 8, 2009, 9:46 am, US News & World Report
Best nursing homes nationwide—a brand-new honor roll; 5 risks linked to some diabetes drugs.
Lilly asks FDA to review weekly diabetes drug
Published July 8, 2009, 7:38 am, Indianapolis Business Journal
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration has accepted their application for the once-a-week diabetes drug exenatide.Exenatide is the primary ingredient of Byetta, a treatment for type 2 diabetes.While Byetta is injected twice a day, the newer drug is intended to be injected weekly ...
Amylin shares rise as FDA reviews diabetes drug
Published July 8, 2009, 7:28 am, INO News
(AP:NEW YORK) Shares of Amylin Pharmaceuticals Inc. jumped Wednesday after the company said the Food and Drug Administration will review the potential once-weekly diabetes drug exenatide LAR.
UPDATE: BEFORE THE BELL -2: US HOT STOCKS TO WATCH
Published July 8, 2009, 6:18 am, INO News
Among the companies whose shares are expected to actively trade in Wednesday's session are ARYx Therapeutics Inc. (ARYX), MSC.Software Corp. (MSCS) and Arena Pharmaceuticals Inc. (ARNA).
BEFORE THE BELL -2: US HOT STOCKS TO WATCH
Published July 8, 2009, 3:30 am, INO News
Among the companies whose shares are expected to actively trade in Wednesday's session are Amgen Inc. (AMGN), Ruby Tuesday Inc. (RT) and Amylin Pharmaceuticals Inc. (AMLN).
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |